title: Clinical and molecular investigation of 19 Japanese cases of glutaric acidemia type 1.
abstract: Glutaric acidemia type 1 (GA1) is a metabolic disease caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH). Untreated patients mostly develop severe striatal degeneration. More than 200 mutations have been reported in the GCDH gene, and common R402W and IVS10-2A>C were found in Caucasian and Chinese/Taiwanese, respectively. However, in Japan, genetic mutations have only been reported in a few cases. Herein, we report the clinical and molecular basis of GA1 in 19 Japanese patients, including six previously reported patients. All cases showed high urinary glutaric acid excretion. Eleven patients were severely impaired (three patients died), three had mild impairment, and five showed normal development. Four of 5 patients that developed normally were detected in the presymptomatic stage by neonatal or sibling screening. Nineteen mutations in 26 alleles were identified, and eight of them (89 or 90delC, Y155C, IVS4+2T＞C, G244S, Q352X, G354A, K361E, and 1144-1145delGC) were novel. S305L (12.1%, 4/34 alleles) was found in several cases, suggesting that this mutation is a common mutation. In contrast, R402W was not identified and IVS10-2A>C was only found in one allele, suggesting that Japanese patients with GA1 show allelic heterogeneity and have a different genetic background to patients from other countries. One of a pair of sisters with the same mutations (M339V/S305L) lacking residual activity was severely retarded, whereas the older girl remains asymptomatic at 22 years of age, indicating that genotype does not necessarily predict GA1 phenotype. We consistently found that there was no association between genotype and phenotype. However, children with mild impairment were diagnosed and treated earlier than severely impaired cases {4.7±2.5 months (range: 2-8 months) vs. 11.6±12.7 months (range: 4-51 months)}. Our results suggest that early detection and treatment but not genotype are associated with better patient outcome, reinforcing the importance of neonatal screening.
authors.affiliation: Department of Pediatrics, Shimane University Faculty of Medicine, Izumo, Shimane, Japan. mushiu1@med.shimane-u.ac.jp
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Mushimoto
authors.forename: Seiji
authors.initials: S
authors.lastname: Fukuda
authors.forename: Yuki
authors.initials: Y
authors.lastname: Hasegawa
authors.forename: Hironori
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Jamiyan
authors.initials: J
authors.lastname: Purevsuren
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.forename: Takeshi
authors.initials: T
authors.lastname: Taketani
authors.forename: Seiji
authors.initials: S
authors.lastname: Yamaguchi
mesh_terms: D000592:Amino Acid Metabolism, Inborn Errors / Q000201:enzymology / Q000235:genetics / Q000401:mortality; D001928:Brain Diseases, Metabolic / Q000201:enzymology / Q000235:genetics / Q000401:mortality; D002675:Child, Preschool; D005260:Female; D023061:Gene Order; D005977:Glutarates / Q000652:urine; D050770:Glutaryl-CoA Dehydrogenase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan; D008297:Male; D009154:Mutation; D010375:Pedigree
chemical_list: D005977:Glutarates; D050770:Glutaryl-CoA Dehydrogenase; C035736:glutaric acid